Last reviewed · How we verify
GLS4
At a glance
| Generic name | GLS4 |
|---|---|
| Also known as | Morphothiadine Mesilate Capsule, Morphothiadine Mesilate Capsules |
| Sponsor | Sunshine Lake Pharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection (PHASE2)
- GLS4/RTV and TAF Drug-drug Interaction (PHASE1)
- The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules (PHASE2)
- A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLS4 CI brief — competitive landscape report
- GLS4 updates RSS · CI watch RSS
- Sunshine Lake Pharma Co., Ltd. portfolio CI